Eli Lilly and Company to Present More Than 40 Abstracts at the Alzheimer's Association International Conference® 2017 (AAIC® 2017)

Data highlights include important health outcomes data emphasizing the need for timely detection and management of Alzheimer's disease

INDIANAPOLIS, July 12, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it will present findings from more than 40 research studies at the upcoming Alzheimer's Association International Conference® 2017 (AAIC® 2017) in London, United Kingdom, July 16 - 20. The data highlight Lilly's broad Alzheimer's pipeline, including potential treatments and diagnostics in various stages of clinical development, in addition to health outcomes data on use of healthcare resources prior to an Alzheimer's disease diagnosis.

"Research shows that Alzheimer's disease begins to develop years before life-impacting symptoms appear. To effectively fight the disease, people with Alzheimer's, their caregivers and their doctors need more productive conversations sooner, with the goal to recognize and diagnose as early as possible," said Phyllis Ferrell, vice president, Global Alzheimer's Disease Platform Team. "We remain committed to finding solutions for Alzheimer's disease and believe promising new therapies are on the horizon."

Of particular interest is one oral presentation which may help inform the future care of Alzheimer's disease:

Additional studies being presented include (please note, all times listed below are UK specific):

Solanezumab Data

Neurodegeneration Data 

Tau Deposit Ab Modulator Data

FabPEG Data

Flortaucipir Data

General Alzheimer's Disease Data

Selective AB 1-42 Antibody Data

About Alzheimer's Disease
Alzheimer's disease is a fatal illness that causes progressive decline in memory and other aspects of cognition. Dementia due to Alzheimer's is the most common form of dementia, accounting for 60 to 80 percent of all cases.i,ii There are currently an estimated 47 million people living with dementia around the world,iii with numbers expected to increase to nearly 75 million by 2030 and 132 million by 2050.iv  Almost 10 million new cases of dementia are diagnosed each year worldwide, implying one new case every 3.2 seconds.v The current annual societal and economic cost of dementia is estimated at more than $800 billion and it is expected to become a trillion dollar disease by 2018.vi

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and www.lilly.com/newsroom/social-channels. P-LLY    

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about investigational treatments and diagnostics for Alzheimer's disease and reflects Lilly's current belief. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that future study results will be consistent with the results to date or that these investigational compounds or diagnostics will achieve primary study endpoints or receive regulatory approvals.  For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

i Alzheimer's Disease International. Dementia statistics. http://www.alz.co.uk/research/statistics. Accessed March 2017.

ii Alzheimer's Association. What Is Dementia? http://www.alz.org/what-is-dementia.asp. Accessed March 2017.

iii Alzheimer's Disease International. Dementia statistics. http://www.alz.co.uk/research/statistics. Accessed March 2017.

iv Alzheimer's Disease International. Dementia statistics. http://www.alz.co.uk/research/statistics. Accessed March 2017.

v Alzheimer's Disease International. Dementia statistics. http://www.alz.co.uk/research/statistics. Accessed March 2017.

vi Alzheimer's Disease International. World Alzheimer Report 2015 The Global Impact of Dementia. https://www.alz.co.uk/research/WorldAlzheimerReport2015.pdf. Accessed March 2017.



Refer to:
Media - Courtney Kasinger; ckasinger@lilly.com; 317.501.7056 (Lilly)
Investors - Phil Johnson; johnson_philip_l@lilly.com; 317.655.6874 (Lilly)

Eli Lilly and Company logo.

View original content:http://www.prnewswire.com/news-releases/eli-lilly-and-company-to-present-more-than-40-abstracts-at-the-alzheimers-association-international-conference-2017-aaic-2017-300486913.html

SOURCE Eli Lilly and Company

News Provided by Acquire Media

Close window | Back to top